Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16584080 | 1.00 | NR5A1 (0.61) | NR5A1KEAP1NFE2L2NPC1RAB9A | |
| SCHEMBL15923173 | 1.00 | NR5A1 (0.61) | NR5A1KEAP1NFE2L2NPC1RAB9A | |
| SCHEMBL28006584 | 1.00 | NR5A1 (0.61) | NR5A1KEAP1NFE2L2NPC1RAB9A | |
| SCHEMBL29038706 | 1.00 | NR5A1 (0.61) | NR5A1KEAP1NFE2L2NPC1RAB9A | |
| SCHEMBL9307111 | 1.00 | NR5A1 (0.61) | NR5A1KEAP1NFE2L2NPC1RAB9A | |
| SCHEMBL28651767 | 1.00 | NR5A1 (0.61) | NR5A1KEAP1NFE2L2NPC1RAB9A | |
| SCHEMBL6717278 | 1.00 | NR5A1 (0.61) | NR5A1KEAP1NFE2L2NPC1RAB9A | |
| SCHEMBL15923618 | 1.00 | NR5A1 (0.61) | NR5A1KEAP1NFE2L2NPC1RAB9A | |
| SCHEMBL2401164 | 0.98 | KEAP1 (0.59) | NR5A1KEAP1NFE2L2NPC1RAB9A | |
| SCHEMBL15923077 | 0.96 | NR5A1 (0.58) | NR5A1KEAP1NFE2L2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7008636-B2 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH (US) | 2006-03-07 | — | — | US | disclosed |
| US-20040214869-A1 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2004-10-28 | — | — | US | disclosed |
| US-6765021-B2 | ANTIDIABETIC AGENTS | WYETH | 2004-07-20 | — | — | US | disclosed |
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-05-01 | — | — | US | disclosed |
| US-6451827-B2 | MODULATING BLOOD GLUCOSE CONCENTRATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20010018525-A1 | 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2001-08-30 | — | — | US | disclosed |
| US-6214877-B1 | ANTIDIABETIC AGENTS; MODULATOR OF GLUCOSE CONCENTRATION | WYETH | 2001-04-10 | — | — | US | disclosed |
| EP-1077929-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061410-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | NR5A1 94/4885KEAP1 1271/4885NFE2L2 563/4885 |
| US-20010018525-A1 | 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | NR5A1 96/4885KEAP1 1265/4885NFE2L2 564/4885 |
| US-20040214869-A1 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | NR5A1 94/4885KEAP1 1271/4885NFE2L2 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.